资讯

Click2Houston19 天
Gene therapy maker Sarepta tells FDA it won't halt shipments despite ...
The FDA said Friday it placed that trial on hold. Sarepta noted that the gene therapy involved in the incident uses “a different dose and is manufactured using a different process,” than Elevidys.
KRON4 News19 天
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite ...
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths by: MATTHEW PERRONE, Associated Press Posted: Jul 19, 2025 / 06:20 AM PDT Updated: Jul 19, 2025 / 06:20 AM PDT ...
Newsday19 天
Gene therapy maker Sarepta tells FDA it won't halt shipments ... - Newsday
The FDA said Friday it placed that trial on hold. Sarepta noted that the gene therapy involved in the incident uses “a different dose and is manufactured using a different process,” than Elevidys.
STAT20 天
Patient dies in Sarepta gene therapy trial, adding to safety concerns
A 51-year-old man died last month after receiving an experimental gene therapy developed by Sarepta Therapeutics for an ultra-rare form of muscular dystrophy, a company spokesperson confirmed ...
来自MSN20 天
FDA to Ask Sarepta to Halt Elevidys Shipments After Deaths - MSN
The regulator is also under pressure for its stance toward Sarepta’s gene therapy, which it approved even though early trials didn’t clearly show it slowed the disease. The deaths pose one of ...
Janesville Gazette19 天
Gene therapy maker Sarepta tells FDA it won't halt shipments despite ...
Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy By MATTHEW PERRONE - AP Health Writer Jul 19, 2025 ...
GEN18 天
StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies
The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier ...